

表五之一 台灣癌症申報發生人數按原發部位及治療方法分類，民國 96 年  
METHODS OF CANCER TREATMENT IN PRIMARY ANATOMIC SITES, 2007

ICD-O-3	原 發 部 位 別 PRIMARY ANATOMIC SITES	個案數 CASE NUMBER
<b>C00-C80</b>	<b>全癌症（總計） ALL SITES</b>	<b>75,769</b>
<b>C00-C14</b>	<b>唇、口腔及咽 LIP, ORAL CAVITY AND PHARYNX</b>	<b>7,217</b>
C00-C14 <sup>4</sup>	口腔、口咽及下咽 ORAL CAVITY, OROPHARYNX AND HYPOPHARYNX	5,458
C00	唇（唇的皮膚 C44.0 除外） LIP (excludes skin of lip C44.0)	185
C01-C02	舌 TONGUE	1,590
C03	齒齦 GUM	378
C04	口底 FLOOR OF MOUTH	127
C05-C06	口腔之其他及未詳細說明部位 OTHER AND UNSPECIFIED PARTS OF MOUTH	1,874
C09-C10	口咽 OROPHARYNX	512
C12-C13	下咽 HYPOPHARYNX	764
C14	咽和唇、口腔及咽之分界不明部位 PHARYNX AND ILL-DEFINED SITES IN LIP, ORAL CAVITY AND PHARYNX	28
C07-C08	主唾液腺 MAJOR SALIVARY GLANDS	180
C11	鼻咽 NASOPHARYNX	1,579
<b>C15-C26, C48</b>	<b>消化器官及腹膜 DIGESTIVE ORGANS AND PERITONEUM</b>	<b>28,729</b>
C15	食道 ESOPHAGUS	1,825
C16	胃 STOMACH	3,612
C17	小腸 SMALL INTESTINE	309

註：1. 自 96 年癌症登記報告起，惡性淋巴瘤從各部位獨立出來計算發生率，並納入排名。惡性淋巴瘤：ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643。

2. 每名個案所接受之治療方式均分別計數，（）內為該治療方式佔該個案數之百分比。

3. 個案有接受放射治療，但病歷相關記錄並未說明在哪裡接受治療；或不知道個案是否有接受放射治療者共 38 筆未列入表中。

4. 口腔、口咽及下咽：包括 ICD-O-3 C00-C06、C09-C10、C12-C14。

申報治療方法 <sup>2</sup> METHODS OF CANCER TREATMENT												ICD-O-3
手術治療 Surgery	放射治療 Radiotherapy	化學治療 Chemotherapy	荷爾蒙 治療 Hormone therapy	免疫治療 Immunotherapy	骨髓/幹細胞 移植或 內分泌治療 Hematologic transplant/ Endocrine procedure	緩和照護 Palliative care	未治療 Without therapy					
40,109 (52.94)	18,197 (24.02)	31,529 (41.61)	7,686 (10.14)	479 (0.63)	303 (0.40)	10,847 (14.32)	10,134 (13.37)					C00-C80
3,778 (52.35)	4,031 (55.85)	3,762 (52.13)	-	-	4 (0.06)	-	-	596 (8.26)	608 (8.42)			C00-C14
3,607 (66.09)	2,623 (48.06)	2,442 (44.74)	-	-	2 (0.04)	-	-	460 (8.43)	443 (8.12)			C00-C14 <sup>4</sup>
165 (89.19)	40 (21.62)	37 (20.00)	-	-	1 (0.54)	-	-	4 (2.16)	10 (5.41)			C00
1,221 (76.79)	624 (39.25)	570 (35.85)	-	-	-	-	-	105 (6.60)	113 (7.11)			C01-C02
293 (77.51)	192 (50.79)	161 (42.59)	-	-	-	-	-	36 (9.52)	25 (6.61)			C03
98 (77.17)	52 (40.94)	52 (40.94)	-	-	-	-	-	9 (7.09)	12 (9.45)			C04
1,414 (75.45)	747 (39.86)	703 (37.51)	-	-	1 (0.05)	-	-	137 (7.31)	155 (8.27)			C05-C06
151 (29.49)	393 (76.76)	384 (75.00)	-	-	-	-	-	50 (9.77)	52 (10.16)			C09-C10
256 (33.51)	559 (73.17)	513 (67.15)	-	-	-	-	-	115 (15.05)	75 (9.82)			C12-C13
9 (32.14)	16 (57.14)	22 (78.57)	-	-	-	-	-	4 (14.29)	1 (3.57)			C14
144 (80.00)	95 (52.78)	53 (29.44)	-	-	-	-	-	17 (9.44)	17 (9.44)			C07-C08
27 (1.71)	1,313 (83.15)	1,267 (80.24)	-	-	2 (0.13)	-	-	119 (7.54)	148 (9.37)			C11
14,154 (49.27)	3,705 (12.90)	10,205 (35.52)	54 (0.19)	47 (0.16)	2 (0.01)	5,052 (17.59)	4,786 (16.66)					C15-C26, C48
542 (29.70)	1,101 (60.33)	1,077 (59.01)	4 (0.22)	5 (0.27)	-	411 (22.52)	261 (14.30)					C15
2,204 (61.02)	257 (7.12)	1,260 (34.88)	9 (0.25)	14 (0.39)	-	753 (20.85)	625 (17.30)					C16
197 (63.75)	15 (4.85)	82 (26.54)	1 (0.32)	1 (0.32)	-	56 (18.12)	50 (16.18)					C17

表五之一 台灣癌症申報發生人數按原發部位及治療方法分類，民國 96 年（續）  
METHODS OF CANCER TREATMENT IN PRIMARY ANATOMIC SITES, 2007 (CONTINUED)

ICD-O-3	原 發 部 位 別 PRIMARY ANATOMIC SITES	個案數 CASE NUMBER
C18-C21	結腸、直腸、乙狀結腸連結部及肛門 COLON, RECTUM, RECTOSIGMOID JUNCTION AND ANUS	10,511
C18	結腸 COLON	6,127
C19-C21	直腸、乙狀結腸連結部及肛門 RECTUM, RECTOSIGMOID JUNCTION AND ANUS	4,384
C22 <sup>5</sup>	肝及肝內膽管 LIVER AND INTRAHEPATIC BILE DUCTS	10,110
C23-C24	膽囊及肝外膽管 GALLBLADDER AND EXTRAHEPATIC BILE DUCTS	804
C25	胰 PANCREAS	1,380
C48	後腹膜腔及腹膜 RETROPERITONEUM AND PERITONEUM	140
C26	消化器官之其他部位及與腹膜分界不明部位 OTHER AND ILL-DEFINED SITES WITHIN DIGESTIVE ORGANS AND PERITONEUM	38
<b>C30-C39</b>	<b>呼吸系統及胸腔內器官 RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS</b>	<b>10,065</b>
C30-C31	鼻腔、副竇、中耳及內耳 NASAL CAVITIES, ACCESSORY SINUSES, MIDDLE EAR AND INNER EAR	150
C32	喉 LARYNX	559
C33-C34	肺、支氣管及氣管 TRACHEA, BRONCHUS AND LUNG	9,059
C38.4	胸膜 PLEURA	55
C37-C38.3, C38.8	胸腺、心臟及縱膈 THYMUS, HEART AND MEDIASTINUM	242
<b>C42</b>	<b>造血系統及網狀內皮系統（白血病除外） HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS (excludes LEUKEMIA)</b>	<b>392</b>
<b>C42<sup>6</sup></b>	<b>白血病 LEUKEMIA</b>	<b>1,513</b>
<b>C40-C41</b>	<b>骨、關節及關節軟骨 BONES, JOINTS AND ARTICULAR CARTILAGE</b>	<b>157</b>

註：1. 自 96 年癌症登記報告起，惡性淋巴瘤從各部位獨立出來計算發生率，並納入排名。惡性淋巴瘤：ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643。

2. 每名個案所接受之治療方式均分別計數，（）內為該治療方式佔該個案數之百分比。

5. 肝及肝內膽管的詳細治療方法分類，請見本年報第 39 頁首次療程的內文說明。

6. 白血病：ICD-O-3 M-98003 - M-99643、M-99803 - M-99893。

申報治療方法 <sup>2</sup> METHODS OF CANCER TREATMENT										ICD-O-3
手術治療 Surgery	放射治療 Radiotherapy	化學治療 Chemotherapy	荷爾蒙 治療 Hormone therapy	免疫治療 Immunotherapy	骨髓/幹細胞 移植或 內分泌治療 Hematologic transplant/ Endocrine procedure	緩和照護 Palliative care	未治療 Without therapy			
8,377 (79.70)	1,240 (11.80)	5,419 (51.56)	17 (0.16)	9 (0.09)	- -	1,257 (11.96)	1,129 (10.74)			C18-C21
4,886 (79.75)	200 (3.26)	3,028 (49.42)	7 (0.11)	4 (0.07)	- -	752 (12.27)	730 (11.91)			C18
3,491 (79.63)	1,040 (23.72)	2,391 (54.54)	10 (0.23)	5 (0.11)	- -	505 (11.52)	399 (9.10)			C19-C21
1,993 (19.71)	786 (7.77)	1,569 (15.52)	- -	10 (0.10)	- -	1,842 (18.22)	2,211 (21.87)			C22
448 (55.72)	86 (10.70)	179 (22.26)	1 (0.12)	4 (0.50)	- -	200 (24.88)	164 (20.40)			C23-C24
276 (20.00)	183 (13.26)	562 (40.72)	5 (0.36)	4 (0.29)	- -	510 (36.96)	330 (23.91)			C25
99 (70.71)	35 (25.00)	43 (30.71)	- -	- -	2 (1.43)	15 (10.71)	10 (7.14)			C48
18 (47.37)	2 (5.26)	14 (36.84)	- -	- -	- -	8 (21.05)	6 (15.79)			C26
<b>1,913 (19.01)</b>	<b>2,937 (29.18)</b>	<b>5,791 (57.54)</b>	<b>8 (0.08)</b>	<b>23 (0.23)</b>	- -	<b>2,774 (27.56)</b>	<b>1,871 (18.59)</b>			<b>C30-C39</b>
99 (66.00)	92 (61.33)	55 (36.67)	- -	- -	- -	9 (6.00)	15 (10.00)			C30-C31
296 (52.95)	311 (55.64)	168 (30.05)	- -	- -	- -	42 (7.51)	60 (10.73)			C32
1,385 (15.29)	2,397 (26.46)	5,442 (60.07)	- -	22 (0.24)	- -	2,676 (29.54)	1,754 (19.36)			C33-C34
9 (16.36)	7 (12.73)	33 (60.00)	- -	1 (1.82)	- -	22 (40.00)	10 (18.18)			C38.4
124 (51.24)	130 (53.72)	93 (38.43)	- -	- -	- -	25 (10.33)	32 (13.22)			C37-C38.3, C38.8
<b>17 (4.34)</b>	<b>82 (20.92)</b>	<b>284 (72.45)</b>	<b>85 (21.68)</b>	<b>6 (1.53)</b>	<b>11 (2.81)</b>	<b>82 (20.92)</b>	<b>64 (16.33)</b>			<b>C42</b>
<b>18 (1.19)</b>	<b>38 (2.51)</b>	<b>1,074 (70.98)</b>	<b>99 (6.54)</b>	<b>12 (0.79)</b>	<b>58 (3.83)</b>	<b>257 (16.99)</b>	<b>288 (19.04)</b>			<b>C42<sup>5</sup></b>
<b>116 (73.89)</b>	<b>38 (24.20)</b>	<b>69 (43.95)</b>	- -	- -	- -	<b>16 (10.19)</b>	<b>15 (9.55)</b>			<b>C40-C41</b>

表五之一 台灣癌症申報發生人數按原發部位及治療方法分類，民國 96 年（續）  
METHODS OF CANCER TREATMENT IN PRIMARY ANATOMIC SITES, 2007 (CONTINUED)

ICD-O-3	原 發 部 位 別 PRIMARY ANATOMIC SITES	個案數 CASE NUMBER
<b>C47, C49</b>	<b>結締組織、軟組織及其他皮下組織 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES</b>	<b>409</b>
<b>C44</b>	<b>皮膚 SKIN</b>	<b>2,427</b>
C44 <sup>7</sup>	皮膚，惡性黑色素瘤 SKIN, MALIGNANT MELANOMA	192
C44	皮膚，非惡性黑色素瘤 SKIN (excludes MALIGNANT MELANOMA)	2,235
<b>C50</b>	<b>女性乳房 FEMALE BREAST</b>	<b>7,502</b>
<b>C50</b>	<b>男性乳房 MALE BREAST</b>	<b>35</b>
<b>C51-C58</b>	<b>女性生殖器官 FEMALE GENITAL ORGANS</b>	<b>4,126</b>
C55	子宮，未明示部位 UTERUS, NOS	11
C53	子宮頸 CERVIX UTERI	1,749
C54	子宮體 CORPUS UTERI	1,165
C56, C57.0-C57.4	卵巢、輸卵管及寬韌帶 OVARY, FALLOPIAN TUBE AND BROAD LIGAMENT	1,047
C51-C52, C57.7-C57.9	陰道、外陰部及其他未詳細說明之女性生殖器官 VAGINA, VULVA, OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS	154
<b>C60-C63</b>	<b>男性生殖器官 MALE GENITAL ORGANS</b>	<b>3,588</b>
C61	攝護腺 PROSTATE GLAND	3,367
C62	睪丸 TESTIS	142
C60, C63	陰莖及其他男性生殖器官 PENIS AND OTHER MALE GENITAL ORGANS	79
<b>C64-C68</b>	<b>泌尿器官 URINARY TRACT</b>	<b>4,022</b>

註：1. 自 96 年癌症登記報告起，惡性淋巴瘤從各部位獨立出來計算發生率，並納入排名。惡性淋巴瘤：ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643。

2. 每名個案所接受之治療方式均分別計數，（）內為該治療方式佔該個案數之百分比。

7. 皮膚，惡性黑色素瘤：ICD-O-3 C44， M-87203 - M-87903。

申報治療方法 <sup>2</sup> METHODS OF CANCER TREATMENT										ICD-O-3
手術治療 Surgery	放射治療 Radiotherapy	化學治療 Chemotherapy	荷爾蒙治療 Hormone therapy	免疫治療 Immunotherapy	骨髓/幹細胞移植或 內分泌治療 Hematologic transplant/ Endocrine procedure	緩和照護 Palliative care	未治療 Without therapy			
325 (79.46)	143 (34.96)	91 (22.25)	3 (0.73)	-	-	-	38 (9.29)	37 (9.05)		C47, C49
2,146 (88.42)	191 (7.87)	65 (2.68)	2 (0.08)	13 (0.54)	-	-	129 (5.32)	190 (7.83)		C44
159 (82.81)	27 (14.06)	25 (13.02)	-	7 (3.65)	-	-	19 (9.90)	16 (8.33)		C44 <sup>6</sup>
1,987 (88.90)	164 (7.34)	40 (1.79)	2 (0.09)	6 (0.27)	-	-	110 (4.92)	174 (7.79)		C44
6,805 (90.71)	2,715 (36.19)	5,065 (67.52)	4,315 (57.52)	10 (0.13)	5 (0.07)	352 (4.69)	296 (3.95)			C50
29 (82.86)	4 (11.43)	12 (34.29)	15 (42.86)	-	-	5 (14.29)	5 (14.29)			C50
2,992 (72.52)	1,363 (33.03)	1,767 (42.83)	89 (2.16)	5 (0.12)	-	274 (6.64)	314 (7.61)			C51-C58
6 (54.55)	1 (9.09)	6 (54.55)	-	-	-	-	-	1 (9.09)		C55
938 (53.63)	937 (53.57)	705 (40.31)	9 (0.51)	1 (0.06)	-	109 (6.23)	167 (9.55)			C53
1,061 (91.07)	343 (29.44)	260 (22.32)	65 (5.58)	2 (0.17)	-	66 (5.67)	63 (5.41)			C54
903 (86.25)	29 (2.77)	754 (72.02)	15 (1.43)	2 (0.19)	-	88 (8.40)	56 (5.35)			C56, C57.0-C57.4
84 (54.55)	53 (34.42)	42 (27.27)	-	-	-	11 (7.14)	27 (17.53)			C51-C52, C57.7-C57.9
1,645 (45.85)	804 (22.41)	171 (4.77)	1,724 (48.05)	29 (0.81)	215 (5.99)	267 (7.44)	422 (11.76)			C60-C63
1,454 (43.18)	761 (22.60)	115 (3.42)	1,721 (51.11)	28 (0.83)	214 (6.36)	248 (7.37)	409 (12.15)			C61
129 (90.85)	28 (19.72)	49 (34.51)	2 (1.41)	-	1 (0.70)	11 (7.75)	5 (3.52)			C62
62 (78.48)	15 (18.99)	7 (8.86)	1 (1.27)	1 (1.27)	-	8 (10.13)	8 (10.13)			C60, C63
3,306 (82.20)	282 (7.01)	1,203 (29.91)	27 (0.67)	304 (7.56)	-	341 (8.48)	391 (9.72)			C64-C68

表五之一 台灣癌症申報發生人數按原發部位及治療方法分類，民國 96 年（續完）  
METHODS OF CANCER TREATMENT IN PRIMARY ANATOMIC SITES, 2007 (CONTINUED)

ICD-O-3	原 發 部 位 別 PRIMARY ANATOMIC SITES	個案數 CASE NUMBER
C67	膀胱 BLADDER	2,050
C64	腎 KIDNEY	798
C65	腎盂 RENAL PELVIS	587
C66	輸尿管 URETER	403
C68.0-C68.1	尿道及其周邊腺體 URETHRA AND PARAURETHRAL GLAND	15
C68.8	跨越泌尿器官兩個以上相鄰部位之病變 OVERLAPPING LESION OF URINARY ORGANS	18
C68.9	泌尿系統，未明示部位 URINARY SYSTEM, NOS	151
C69	眼及淚腺 EYE AND LACRIMAL GLAND	50
C70-C72	中樞神經系統 BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM	643
C71	腦 BRAIN	572
C70, C72	其他神經系統及未詳細說明部位 OTHER AND UNSPECIFIED PARTS OF NERVOUS SYSTEM	71
C73	甲狀腺 THYROID GLAND	1,837
C74-C75	其他內分泌腺 OTHER ENDOCRINE GLANDS	59
C76	其他分界不明的部位 OTHER AND ILL-DEFINED SITES	15
C80	不明原發部位 UNKNOWN PRIMARY SITES	936
	惡性淋巴瘤 MALIGNANT LYMPHOMA (ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643)	2,047

註：1. 自 96 年癌症登記報告起，惡性淋巴瘤從各部位獨立出來計算發生率，並納入排名。惡性淋巴瘤：ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643。

2. 每名個案所接受之治療方式均分別計數，（）內為該治療方式佔該個案數之百分比。

申報治療方法 <sup>2</sup> METHODS OF CANCER TREATMENT										ICD-O-3
手術治療 Surgery	放射治療 Radiotherapy	化學治療 Chemotherapy	荷爾蒙治療 Hormone therapy	免疫治療 Immunotherapy	骨髓/幹細胞移植或 內分泌治療 Hematologic transplant/ Endocrine procedure	緩和照護 Palliative care	未治療 Without therapy			
1,797 (87.66)	136 (6.63)	801 (39.07)	16 (0.78)	248 (12.10)	-	155 (7.56)	148 (7.22)			C67
587 (73.56)	47 (5.89)	68 (8.52)	7 (0.88)	31 (3.88)	-	79 (9.90)	109 (13.66)			C64
480 (81.77)	42 (7.16)	167 (28.45)	2 (0.34)	7 (1.19)	-	47 (8.01)	47 (8.01)			C65
297 (73.70)	39 (9.68)	101 (25.06)	2 (0.50)	8 (1.99)	-	38 (9.43)	64 (15.88)			C66
11 (73.33)	1 (6.67)	4 (26.67)	-	2 (13.33)	-	1 (6.67)	2 (13.33)			C68.0-C68.1
16 (88.89)	3 (16.67)	6 (33.33)	-	-	-	1 (5.56)	2 (11.11)			C68.8
118 (78.15)	14 (9.27)	56 (37.09)	-	8 (5.30)	-	20 (13.25)	19 (12.58)			C68.9
<b>36 (72.00)</b>	<b>9 (18.00)</b>	<b>14 (28.00)</b>	-	-	-	<b>2 (4.00)</b>	<b>1 (2.00)</b>			<b>C69</b>
<b>493 (76.67)</b>	<b>385 (59.88)</b>	<b>187 (29.08)</b>	<b>2 (0.31)</b>	<b>5 (0.78)</b>	-	<b>74 (11.51)</b>	<b>58 (9.02)</b>			<b>C70-C72</b>
430 (75.17)	350 (61.19)	179 (31.29)	2 (0.35)	5 (0.87)	-	69 (12.06)	56 (9.79)			C71
63 (88.73)	35 (49.30)	8 (11.27)	-	-	-	5 (7.04)	2 (2.82)			C70, C72
<b>1,638 (89.17)</b>	<b>892 (48.56)</b>	<b>24 (1.31)</b>	<b>735 (40.01)</b>	<b>2 (0.11)</b>	-	<b>94 (5.12)</b>	<b>106 (5.77)</b>			<b>C73</b>
<b>39 (66.10)</b>	<b>9 (15.25)</b>	<b>23 (38.98)</b>	<b>1 (1.69)</b>	-	<b>2 (3.39)</b>	<b>3 (5.08)</b>	<b>9 (15.25)</b>			<b>C74-C75</b>
<b>3 (20.00)</b>	<b>1 (6.67)</b>	<b>1 (6.67)</b>	-	-	-	<b>6 (40.00)</b>	<b>8 (53.33)</b>			<b>C76</b>
111 (11.86)	213 (22.76)	264 (28.21)	4 (0.43)	-	-	280 (29.91)	370 (39.53)			C80
545 (26.62)	355 (17.34)	1,457 (71.18)	548 (26.77)	19 (0.93)	10 (0.49)	205 (10.01)	295 (14.41)			



表五之二 台灣白血病及惡性淋巴瘤申報發生人數按治療方法分類，民國 96 年  
METHODS OF CANCER TREATMENT OF LEUKEMIA AND LYMPHOMA, 2007

<p style="text-align: center;">白 血 病 及 惡 性 淋 巴 瘤 HEMATOPOIETIC AND LYMPHOID TUMORS</p>	<p style="text-align: center;">個案數 CASE NUMBER</p>
<p><b>白血病</b> <b>LEUKEMIA (ICD-O-3 M-98003 - M-99643、M-99803 - M-99893)</b></p> <p>急性淋巴芽細胞白血病 ACUTE LYMPHOBLASTIC LEUKEMIA (ICD-O-3 M-98353 - M-98373)</p> <p>慢性淋巴球白血病 CHRONIC LYMPHOCYTIC LEUKEMIA (ICD-O-3 M-98233)</p> <p>急性骨髓樣白血病 ACUTE MYELOID LEUKEMIA (ICD-O-3 M-98403、M-98613、M-98663、M-98673、M-98713 - M-98743、M-98953 - M-98973、M-99203)</p> <p>慢性骨髓樣白血病 CHRONIC MYELOID LEUKEMIA (ICD-O-3 M-98633、M-98753、M-98763、M-99453、M-99463、M-99633)</p> <p>其他類型白血病<sup>3</sup> LEUKEMIA excludes Acute lymphoblastic leukemia, Chronic lymphocytic leukemia, acute myeloid leukemia and Chronic myeloid leukemia</p>	<p style="text-align: right;"><b>1,513</b></p> <p style="text-align: right;">223</p> <p style="text-align: right;">96</p> <p style="text-align: right;">626</p> <p style="text-align: right;">182</p> <p style="text-align: right;">386</p>
<p><b>惡性淋巴瘤</b> <b>MALIGNANT LYMPHOMA (ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643)</b></p> <p>何杰金氏淋巴瘤 HODGKIN LYMPHOMA (ICD-O-3 M-96503 - M-96673)</p> <p>非何杰金氏淋巴瘤 NON-HODGKIN LYMPHOMA (ICD-O-3 M-95903 - M-95963、M-96703 - M-97293、M-97503 - M-97583、M-97643)</p>	<p style="text-align: right;"><b>2,047</b></p> <p style="text-align: right;">145</p> <p style="text-align: right;">1,902</p>

註：1. 自 96 年癌症登記報告起，惡性淋巴瘤從各部位獨立出來計算發生率，並納入排名。惡性淋巴瘤：ICD-O-3 M-95903 - M-97293、M-97503 - M-97583、M-97643。

2. 每名個案所接受之治療方式均分別計數，（）內為該治療方式佔該個案數之百分比。

3. 其他類型白血病：除急性淋巴芽細胞白血病、慢性淋巴球白血病、急性骨髓樣白血病、慢性骨髓樣白血病外之所有白血病代碼。

申報治療方法<sup>2</sup> METHODS OF CANCER TREATMENT

手術治療 Surgery	放射治療 Radiotherapy	化學治療 Chemotherapy	荷爾蒙治療 Hormone therapy	免疫治療 Immunotherapy	骨髓/幹細胞移植或內分泌治療 Hematologic transplant/ Endocrine procedure	緩和照護 Palliative care	未治療 Without therapy
<b>18 (1.19)</b>	<b>38 (2.51)</b>	<b>1,074 (70.98)</b>	<b>99 (6.54)</b>	<b>12 (0.79)</b>	<b>58 (3.83)</b>	<b>257 (16.99)</b>	<b>288 (19.04)</b>
-	14 (6.28)	214 (95.96)	51 (22.87)	1 (0.45)	14 (6.28)	19 (8.52)	6 (2.69)
2 (2.08)	-	58 (60.42)	12 (12.50)	-	-	5 (5.21)	34 (35.42)
2 (0.32)	15 (2.40)	483 (77.16)	19 (3.04)	2 (0.32)	29 (4.63)	114 (18.21)	90 (14.38)
2 (1.10)	2 (1.10)	149 (81.87)	3 (1.65)	2 (1.10)	2 (1.10)	20 (10.99)	24 (13.19)
12 (3.11)	7 (1.81)	170 (44.04)	14 (3.63)	7 (1.81)	13 (3.37)	99 (25.65)	134 (34.72)
<b>545 (26.62)</b>	<b>355 (17.34)</b>	<b>1,457 (71.18)</b>	<b>548 (26.77)</b>	<b>19 (0.93)</b>	<b>10 (0.49)</b>	<b>205 (10.01)</b>	<b>295 (14.41)</b>
40 (27.59)	56 (38.62)	128 (88.28)	11 (7.59)	-	2 (1.38)	9 (6.21)	8 (5.52)
505 (26.55)	299 (15.72)	1,329 (69.87)	537 (28.23)	19 (1.00)	8 (0.42)	196 (10.30)	287 (15.09)